

# TESTIS

<b>Hospital Name/Address</b>
------------------------------

<b>Patient Name/Information</b>
---------------------------------

Type of Specimen \_\_\_\_\_

Histopathologic Type \_\_\_\_\_

Tumor Size \_\_\_\_\_

Laterality: ☐ Bilateral ☐ Left ☐ Right

## DEFINITIONS

<b>Pathologic</b>	<b>Primary Tumor (T)<sup>(1)</sup></b>
<input type="checkbox"/>	pTX Primary tumor cannot be assessed (if no radical orchiectomy has been performed, TX is used)
<input type="checkbox"/>	pT0 No evidence of primary tumor (e.g., histologic scar in testis)
<input type="checkbox"/>	pTis Intratubular germ cell neoplasia (carcinoma <i>in situ</i> )
<input type="checkbox"/>	PT1 Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis
<input type="checkbox"/>	pT2 Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis
<input type="checkbox"/>	PT3 Tumor invades the spermatic cord with or without vascular/lymphatic invasion
<input type="checkbox"/>	pT4 Tumor invades the scrotum with or without vascular/lymphatic invasion

## Notes

1. Except for pTis and pT4, extent of primary tumor is classified as radical orchiectomy. TX may be used for other categories in the absence of radical orchiectomy.

<b>Clinical</b>	<b>Primary Tumor (T)</b>
<input type="checkbox"/>	Tumor stage is generally determined after orchiectomy at which time a pathologic stage is assigned.

<b>Pathologic</b>	<b>Regional Lymph Nodes (N)</b>
<input type="checkbox"/>	pNX Regional lymph nodes cannot be assessed
<input type="checkbox"/>	pN0 No regional lymph node metastasis
<input type="checkbox"/>	pN1 Metastasis with a lymph node mass 2 cm or less in greatest dimension and less than or equal to 5 nodes positive, none more than 2 cm in greatest dimension
<input type="checkbox"/>	pN2 Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than 5 nodes positive, none more than 5 cm; or evidence of extranodal extension of tumor
<input type="checkbox"/>	pN3 Metastasis with a lymph node mass more than 5 cm in greatest dimension

<b>Clinical</b>	<b>Regional Lymph Nodes (N)</b>
<input type="checkbox"/>	NX Regional lymph nodes cannot be assessed
<input type="checkbox"/>	N0 No regional lymph node metastasis
<input type="checkbox"/>	N1 Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2 cm in greatest dimension
<input type="checkbox"/>	N2 Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension
<input type="checkbox"/>	N3 Metastasis with a lymph node mass more than 5 cm in greatest dimension

<b>Clinical</b>	<b>Pathologic</b>	<b>Distant Metastasis (M)</b>
<input type="checkbox"/>	<input type="checkbox"/>	MX Distant metastasis cannot be assessed
<input type="checkbox"/>	<input type="checkbox"/>	M0 No distant metastasis
<input type="checkbox"/>	<input type="checkbox"/>	M1 Distant metastasis
<input type="checkbox"/>	<input type="checkbox"/>	M1a Non-regional nodal or pulmonary metastasis
<input type="checkbox"/>	<input type="checkbox"/>	M1b Distant metastasis other than to non-regional lymph nodes and lungs
		Biopsy of metastatic site performed..... <input type="checkbox"/> Y..... <input type="checkbox"/> N
		Source of pathologic metastatic specimen _____

		<b>Serum Tumor Markers (S)</b> ( <i>N indicates the upper limit of normal for the LDH assay</i> )
<input type="checkbox"/>	<input type="checkbox"/>	SX Marker studies not available or not performed
<input type="checkbox"/>	<input type="checkbox"/>	S0 Marker study levels within normal limits
<input type="checkbox"/>	<input type="checkbox"/>	S1 LDH < 1.5 x N AND hCG (mIU/ml) < 5000 AND AFP (ng/ml) < 1000
<input type="checkbox"/>	<input type="checkbox"/>	S2 LDH 1.5-10 x N OR hCG (mIU/ml) 5000-50,000 OR AFP (ng/ml) 1000-10,000
<input type="checkbox"/>	<input type="checkbox"/>	S3 LDH > 10 x N OR hCG (mIU/ml) > 50,000 OR AFP (ng/ml) > 10,000

(continued on reverse side)

Clinical	Pathologic	Stage Grouping				
<input type="checkbox"/>	<input type="checkbox"/>	0	pTis	N0	M0	S0
<input type="checkbox"/>	<input type="checkbox"/>	I	pT1-4	N0	M0	SX
<input type="checkbox"/>	<input type="checkbox"/>	IA	pT1	N0	M0	S0
<input type="checkbox"/>	<input type="checkbox"/>	IB	pT2	N0	M0	S0
			pT3	N0	M0	S0
			pT4	N0	M0	S0
<input type="checkbox"/>	<input type="checkbox"/>	IS	Any pT/Tx	N0	M0	S1-3
<input type="checkbox"/>	<input type="checkbox"/>	II	Any pT/Tx	N1-3	M0	SX
<input type="checkbox"/>	<input type="checkbox"/>	IIA	Any pT/Tx	N1	M0	S0
			Any pT/Tx	N1	M0	S1
<input type="checkbox"/>	<input type="checkbox"/>	IIB	Any pT/Tx	N2	M0	S0
			Any pT/Tx	N2	M0	S1
<input type="checkbox"/>	<input type="checkbox"/>	IIC	Any pT/Tx	N3	M0	S0
			Any pT/Tx	N3	M0	S1
<input type="checkbox"/>	<input type="checkbox"/>	III	Any pT/Tx	Any N	M1	SX
<input type="checkbox"/>	<input type="checkbox"/>	IIIA	Any pT/Tx	Any N	M1a	S0
			Any pT/Tx	Any N	M1a	S1
<input type="checkbox"/>	<input type="checkbox"/>	IIIB	Any pT/Tx	N1-3	M0	S2
			Any pT/Tx	Any N	M1a	S2
<input type="checkbox"/>	<input type="checkbox"/>	IIIC	Any pT/Tx	N1-3	M0	S3
			Any pT/Tx	Any N	M1a	S3
			Any pT/Tx	Any N	M1b	Any S

# Notes

## Additional Descriptors

### Lymphatic Vessel Invasion (L)

LX Lymphatic vessel invasion cannot be assessed

L0 No lymphatic vessel invasion

L1 Lymphatic vessel invasion

### Venous Invasion (V)

VX Venous invasion cannot be assessed

V0 No venous invasion

V1 Microscopic venous invasion

V2 Macroscopic venous invasion

## Residual Tumor (R)

- ☐ RX Presence of residual tumor cannot be assessed
- ☐ R0 No residual tumor
- ☐ R1 Microscopic residual tumor
- ☐ R2 Macroscopic residual tumor

## Additional Descriptors


For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

- ☐ **m suffix** indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
- ☐ **y prefix** indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy.
- ☐ **r prefix** indicates a recurrent tumor when staged after a disease-free interval, and is identified by the “r” prefix: rTNM.
- ☐ **a prefix** designates the stage determined at autopsy: aTNM.

## Prognostic Indicators (if applicable)

## ILLUSTRATION

Indicate on diagram primary tumor and regional nodes involved.



Physician's Signature \_\_\_\_\_ Date \_\_\_\_\_